Stock AnalizBruker Corp. BRKR
Biotechnology: Laboratory Analytical Instruments · data as of November 13, 2026
Bruker Corp. (BRKR) is a industrial company listed in the US with a market value of about $9.4B. In the twelve months to September 30, 2026 it had revenue of $3.5B and net income of -$167M, a net margin of -4.8%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 38.4, 5-year revenue growth of 12% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
Score: 1.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5B | $3.4B | $3.4B | $3.0B | $2.5B | $2.4B | $2.0B | $2.1B | $1.9B | $1.8B | $1.6B |
| Net income | -$167M | -$9M | $113M | $427M | $297M | $277M | $158M | $197M | $180M | $79M | $154M |
| Free cash flow | $245M | $43M | $136M | $243M | $145M | $190M | $235M | $140M | $190M | $111M | $94M |
| EPS (diluted) | $-1.10 | $-0.15 | $0.76 | $2.90 | $0.00 | $0.00 | $0.00 | $0.00 | $1.14 | $0.49 | $0.95 |
| Net margin | -4.8% | -0.2% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% |
| ROIC | — | 1.2% | 3.5% | 12.4% | 13.0% | 12.0% | 9.5% | 11.9% | 15.7% | 15.2% | 14.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $68.00, 10% above the current price; targets range from $55.00 to $85.00; the consensus rating is “Buy”; expected EPS is $2.14 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Bruker stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bruker pay a dividend?
Yes. The dividend yield is about 0.32%, and it has paid dividends for 10 years in our data.
Is Bruker a good stock to buy?
We do not give buy or sell advice. Bruker scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.